Literature DB >> 7920673

Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen.

W Bushman1, W D Steers, J M Meythaler.   

Abstract

Patients with hereditary spastic paraplegia (HSP), a degenerative central nervous system disorder characterized by progressive lower extremity spasticity, frequently experience symptoms of voiding dysfunction. Urodynamic evaluation of patients with HSP has not been reported, and the etiology of voiding dysfunction remains unexplained. We present our evaluation of three men (ages 42-62 years) with this rare syndrome. Urgency of urination was a uniform and dominant complaint, and two patients regularly experienced urge incontinence. Other symptoms included frequency (n = 3), nocturia (n = 3), and diminished force of stream (n = 1). Postvoid residual volumes were less than 25 ml in all patients. On urodynamic evaluation the two patients with urge incontinence displayed cystometric evidence of involuntary detrusor contractions. Pelvic floor EMG recordings suggested detrusor-sphincter dyssynergia (DSD). In addition, one patient exhibited markedly diminished bladder compliance (1.0 ml/cm H2O) and capacity (50 ml). All patients reported marked symptomatic improvement when treated with continuous intrathecal baclofen. Evaluation during baclofen treatment revealed increases in bladder compliance and capacity, with apparent resolution of DSD in one patient. Voiding symptoms in these patients most likely arise from a neurogenic etiology; however, a contributory role for chronic outlet obstruction from striated muscle spasticity may also exist.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7920673     DOI: 10.1002/nau.1930120210

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  11 in total

Review 1.  Hereditary spastic paraparesis: a review of new developments.

Authors:  C McDermott; K White; K Bushby; P Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

Review 2.  CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.

Authors:  Karl-Erik Andersson; Rikard Pehrson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Intrathecal Baclofen therapy in Germany: Proceedings of the IAB-Interdisciplinary Working Group for Movement Disorders Consensus Meeting.

Authors:  D Dressler; S Berweck; A Chatzikalfas; M Ebke; B Frank; S Hesse; M Huber; J K Krauss; K-H Mücke; A Nolte; H-D Oelmann; P W Schönle; M Schmutzler; H Pickenbrock; C Van der Ven; N Veelken; M Vogel; T Vogt; F Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2015-07-16       Impact factor: 3.575

Review 4.  Pure hereditary spastic paraplegia.

Authors:  E Reid
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

Review 5.  Neural control of the lower urinary tract.

Authors:  William C de Groat; Derek Griffiths; Naoki Yoshimura
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

6.  Urodynamic evaluation of patients with autosomal dominant pure spastic paraplegia linked to chromosome 2p21-p24.

Authors:  L N Jensen; T Gerstenberg; E B Kallestrup; P Koefoed; J Nordling; J E Nielsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

7.  Health survey of adults with hereditary spastic paraparesis compared to population study controls.

Authors:  Krister W Fjermestad; Øivind J Kanavin; Eva E Næss; Lise B Hoxmark; Grete Hummelvoll
Journal:  Orphanet J Rare Dis       Date:  2016-07-13       Impact factor: 4.123

Review 8.  Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies.

Authors:  John T Stoffel
Journal:  Transl Androl Urol       Date:  2016-02

9.  Gastrointestinal and urinary complaints in adults with hereditary spastic paraparesis.

Authors:  Øivind J Kanavin; Krister W Fjermestad
Journal:  Orphanet J Rare Dis       Date:  2018-04-16       Impact factor: 4.123

10.  Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies.

Authors:  Riccardo Bientinesi; Carlo Gandi; PierFrancesco Bassi
Journal:  Int Neurourol J       Date:  2020-06-30       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.